Advertisement

Table of Contents

August 15, 2019; 134 (7)

BLOOD COMMENTARY

PLENARY PAPER

BLOOD SPOTLIGHT

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

  • Prevalence of <em>BTK</em> and <em>PLCG2</em> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
    Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
    Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier, Damien Roos-Weil, Lise Willems, Anne-Sophie Michallet, Alain Delmer, Katia Hormigos, Vincent Levy, Florence Cymbalista and Fanny Baran-Marszak on behalf of the French Innovative Leukemia Organization (FILO) CLL Group

THROMBOSIS AND HEMOSTASIS

BLOOD WORK

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS